HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) 067967.Supplemental Data All Versions of this Article: clinchem.2006.067967v1 52/7/1267    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Warshawsky, I. Articles by Natowicz, M. R. Search for Related Content PubMed PubMed Citation Articles by Warshawsky, I. Articles by Natowicz, M. R. Related Collections Molecular Diagnostics and Genetics

Multiplex Ligation-Dependent Probe Amplification for Rapid Detection of Proteolipid Protein 1 Gene Duplications and Deletions in Affected Males and Carrier Females with Pelizaeus–Merzbacher Disease

¹ Department of Clinical Pathology, ² Brain Tumor Institute, ³ Department of Pediatrics, ⁴ Department of Neurology, and ⁵ Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
⁶ Institute of Human Genetics, University Hospital Eppendorf, Hamburg, Germany.
⁷ Department of Human Genetics, Medical University of Vienna, Vienna, Austria.
⁸ Department of Pediatrics and Pediatric Neurology, Georg August University, Göttingen, Germany.

^aAddress correspondence to this author at: Department of Clinical Pathology/L30, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Fax 216-445-9444; e-mail warshai{at}ccf.org.

Background: Pelizaeus–Merzbacher disease is a rare X-linked neurodegenerative disorder caused by sequence variations in the proteolipid protein 1 gene (PLP1). PLP1 gene duplications account for 50%–75% of cases and point variations for 15%–20% of cases; deletions and insertions occur infrequently. We used multiplex ligation-dependent probe amplification (MLPA) to detect PLP1 gene alterations, especially gene duplications and deletions.

Methods: We performed MLPA on 102 samples from individuals with diverse PLP1 gene abnormalities and from controls, including 50 samples previously characterized for the PLP1 gene by quantitative PCR but which were anonymized for prior results and sex.

Results: All males with PLP1 gene duplications (n = 13), 1 male with a triplication, 2 males with whole gene deletions, and all controls (n = 72) were unambiguously assigned to their correct genotype. Of 4 female carriers tested by MLPA and quantitative PCR, 3 were duplication carriers by both methods, and 1 was a triplication carrier by MLPA and a duplication carrier by quantitative PCR. For 1 sample with a partial deletion, MLPA showed exon 3 deleted but PCR showed exons 3 and 4 deleted. Sequence analysis of 2 samples with reduced dosage for exons 3 and 5 revealed point variations overlapping the annealing site for the corresponding MLPA probe. The precision of MLPA analysis was excellent and comparable to or better than quantitative PCR, with CVs of 4.3%–9.8%.

Conclusions: MLPA is a rapid and reliable method to determine PLP1 gene copies. Samples with partial PLP1 gene dosage alterations require confirmation with a non-MLPA method.